FDA Issues Massive Eye Drop Recall Affecting Major Pharmacy Chains
The U.S. Food and Drug Administration announced on Friday a sweeping recall of more than 3 million bottles of over-the-counter eye drops sold at Walgreens, CVS, and Rite Aid locations nationwide. The recall stems from sterility failures identified during routine manufacturing inspections at a shared contract facility.
The affected products include multiple formulations of lubricating eye drops, redness relief drops, and allergy eye drops distributed under each chain pharmacy private label brand. According to the FDA safety communication, the products were manufactured between October 2025 and March 2026 at a facility in New Jersey.
What Triggered the Recall
FDA investigators discovered several critical deviations from current Good Manufacturing Practice (cGMP) requirements during an inspection that began in late February 2026. The findings included:
- Failure to maintain sterile conditions in filling areas during production shifts
- Inadequate environmental monitoring for microbial contamination
- Incomplete batch testing records for several production lots
- Deficiencies in the facility air handling and filtration systems
While no confirmed infections have been directly linked to the recalled products as of April 4, the FDA stressed that using contaminated eye drops can lead to serious and potentially sight-threatening infections.
"Ophthalmic products require the highest standards of sterility. The conditions we observed at this facility represent unacceptable risks to patient safety," an FDA spokesperson said in a statement accompanying the recall notice.
Which Products Are Affected
The recall covers a broad range of store-brand eye care products. Consumers should check the lot numbers printed on their packaging against the lists published on each retailer website. The FDA has also posted a comprehensive database of affected National Drug Code (NDC) numbers on its recall page.
Walgreens confirmed that approximately 1.2 million units of its Walgreens-brand eye drops are included. CVS Health stated that roughly 1.1 million units of CVS-branded products are part of the recall, while Rite Aid accounts for the remaining 700,000 units.
Consumer Guidance
The FDA urges consumers who have purchased any of the affected products to stop using them immediately and return them to the pharmacy for a full refund. Individuals who have experienced unusual eye redness, pain, discharge, or changes in vision after using these products should seek medical attention promptly.
Ophthalmologist Dr. Rebecca Torres of the American Academy of Ophthalmology noted that contaminated eye drops have been an ongoing concern in recent years. "We saw devastating outcomes from the EzriCare recall in 2023, including infections with drug-resistant bacteria. This new recall underscores how vulnerable the ophthalmic drug supply chain remains," she said.
Regulatory Fallout
The contract manufacturer, which the FDA has not publicly named pending ongoing investigation, has voluntarily halted production at the affected facility. The agency said it is working with the company on a corrective action plan and will conduct a follow-up inspection before any production resumes.
This recall marks one of the largest eye drop recalls in FDA history by unit volume, though the agency emphasized that the action is precautionary. Congressional leaders on the Senate Health, Education, Labor, and Pensions Committee have already called for hearings on contract manufacturing oversight for ophthalmic products.
Consumers can report adverse events related to these products through the FDA MedWatch Safety Reporting program.
